Dequalinium
As of the edition of 20 October 2026, Dequalinium is a small molecule: marketed, first approved in 2018 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Vablys
- First approved
- 8 February 2018 (FR)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Duchesnay; 2 holders in all
- Withdrawn from market
- 1 January 1984 (in some regions)
- Registered trials
- 3, 1 stopped early
- Disease areas
- Infections; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 2 | 1 | 0 | 1 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Duchesnay | Applicant | 2021 to now |